Did You Know

Several of the largest A- series (Sierra Neuropharma at $21 Million) and B-series (Taligen Therapeutics at $65 Million) investments in the nation during the past 18 months have been in this region.

Successful recent exits in the Rocky Mountain region include:

  • Ventana Medical Systems, acquired by Roche for $3.4 billion
  • Myogen, acquired by Gilead for $2.5 billion
  • Pharmion, acquired by Celgene for $2.9 billion
  • Sirna, acquired by Merck for $1.1 billion
  • Zevex, acquired by Moog for $83.8 million
  • Insmed, acquired by Merck for $130 million

Don’t miss this chance to participate in some of the newest deals and meet those who are shaping the future landscape of the life sciences industry.

Registration is now open!

Investors

Abbott

Bay City Capital

Biogen Idec


Celgene Corporation

Chart Life Science

Frazier Healthcare Ventures


Genetech

H.I.G. BioVentures

High Country Venture


Hunt BioVentures

Johnson & Johnson

KELD LLC


KRG Capital Parnters, LLC

Lilly Ventures

Mesa Verde Venture Partners


Morgenthaler Venture

NovaQuest

Novartis Venture Fund


PraireGold Venture Partners

Puente Partners

REDSCRIPT Ventures


Rocky Mountain Venture Capital Association

Sequel Ventures

Skyline Ventures


Sun Mountain Capital

Technology Partners

Telegraph Hill Partners


Thomas, McNereny & Partners

vSpring Capital

Yasuda Enterprise Development